Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 12/20 | 0.61 |
| ▸ | CDK8 | P49336 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320052 | 0.89 | KIT (0.62) | KITCDK8NTRK1DYRK1AAAK1 | |
| SCHEMBL8321131 | 0.89 | KIT (0.61) | KITCDK8NTRK1DYRK1AAAK1 | |
| SCHEMBL8321129 | 0.87 | CDK8 (0.69) | KITCDK8NTRK1DYRK1AAAK1 | |
| SCHEMBL8322704 | 0.85 | CDK8 (0.66) | KITCDK8NTRK1DYRK1A | |
| SCHEMBL8313522 | 0.84 | KIT (0.78) | KITCDK8DYRK1AAAK1PIK3CA | |
| SCHEMBL13745361 | 0.83 | CDK8 (0.77) | KITCDK8NTRK1DYRK1A | |
| SCHEMBL13745494 | 0.83 | KIT (0.71) | KITCDK8NTRK1DYRK1A | |
| SCHEMBL12829448 | 0.82 | KIT (0.63) | KITCDK8DYRK1AAAK1PIK3CA | |
| SCHEMBL12763561 | 0.80 | CDK8 (0.65) | KITCDK8DYRK1AAAK1 | |
| SCHEMBL8319988 | 0.80 | CDK8 (0.72) | KITCDK8DYRK1APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | KIT 3148/4885CDK8 360/4885NTRK1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.